Why is EXELIXIS, stock price going up?
Bulls say
Regulatory approval prospects
Statistically significant overall survival improvement in the pivotal phase 3 trial strengthens the case for zanzalintinib approval and would bolster commercial prospects in colorectal cancer.
Patent protection
Federal Circuit affirmation of key patents covering the crystalline form of cabozantinib preserves patent-based exclusivity and lowers the risk of an earlier generic competitor, supporting the drug's revenue runway.
Competitive dynamics
Regulatory and commercial barriers around Omcazio, including bioequivalence pathway limitations and the need to build a commercial salesforce, reduce immediate competitive pressure on Cabometyx's market share.
Regulatory scrutiny
FDA requests for updated safety and efficacy data and an extended review signal heightened regulatory scrutiny that increases uncertainty around zanzalintinib's approval process and could raise stock volatility.
Label risk
Missing an overall survival co‑primary endpoint in patients without active liver metastases raises the risk that an approved label could exclude that population and materially shrink zanzalintinib's addressable market.
Patent cliff and revenue risk
A defined patent cliff for cabozantinib creates a potential revenue gap that zanzalintinib and earlier-stage programs must replace to avoid a significant decline in company sales.
